Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Avorn

Showing results (51-60 of 184) with videos related to

Pageof 19
Sort By:
JAMA|April 5, 1985
Physician education and cost containmentS B Soumerai, J Avorn
Annals of Internal Medicine|August 1, 1995
Drug use in the nursing homeJ Avorn, J H Gurwitz
The American Journal of Medicine|July 1, 1982
Scientific versus commercial sources of influence on the prescribing behavior of physiciansJ Avorn, M Chen, R Hartley
Drugs & Aging|September 1, 1995
Epidemiology of adverse drug events in the nursing home settingJ Monette, J H Gurwitz, J Avorn
Clinical Pharmacology and Therapeutics|August 22, 2013
Clinical and regulatory features of drugs not initially approved by the FDAB Wang, J Avorn, A S Kesselheim
Clinical Pharmacology and Therapeutics|June 1, 2013
Defining "innovativeness" in drug development: a systematic reviewA S Kesselheim, B Wang, J Avorn
JAMA|January 17, 1986
Increased antidepressant use in patients prescribed beta-blockersJ Avorn, D E Everitt, S Weiss
The Journal of Rheumatology|July 29, 2000
Patterns of drug use in rheumatoid arthritisA Bérard, D H Solomon, J Avorn
Clinical Pharmacology and Therapeutics|January 1, 1996
The impact of sedative-hypnotic use on sleep symptoms in elderly nursing home residentsM Monane, R J Glynn, J Avorn
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 3, 1999
Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatmentR L Bohn, A B Colowick, J Avorn
Pageof 19

Showing results (51-60 of 184) with videos related to

Sort By:
Pageof 19
JAMA|April 5, 1985
Physician education and cost containmentS B Soumerai, J Avorn
Annals of Internal Medicine|August 1, 1995
Drug use in the nursing homeJ Avorn, J H Gurwitz
The American Journal of Medicine|July 1, 1982
Scientific versus commercial sources of influence on the prescribing behavior of physiciansJ Avorn, M Chen, R Hartley
Drugs & Aging|September 1, 1995
Epidemiology of adverse drug events in the nursing home settingJ Monette, J H Gurwitz, J Avorn
Clinical Pharmacology and Therapeutics|August 22, 2013
Clinical and regulatory features of drugs not initially approved by the FDAB Wang, J Avorn, A S Kesselheim
Clinical Pharmacology and Therapeutics|June 1, 2013
Defining "innovativeness" in drug development: a systematic reviewA S Kesselheim, B Wang, J Avorn
JAMA|January 17, 1986
Increased antidepressant use in patients prescribed beta-blockersJ Avorn, D E Everitt, S Weiss
The Journal of Rheumatology|July 29, 2000
Patterns of drug use in rheumatoid arthritisA Bérard, D H Solomon, J Avorn
Clinical Pharmacology and Therapeutics|January 1, 1996
The impact of sedative-hypnotic use on sleep symptoms in elderly nursing home residentsM Monane, R J Glynn, J Avorn
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 3, 1999
Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatmentR L Bohn, A B Colowick, J Avorn
Pageof 19